Pharmathene Inc (PIP) 2.89 $PIP PharmAthene Ann
Post# of 273249
Posted On: 09/26/2016 5:00:51 AM
Pharmathene Inc (PIP) 2.89 $PIP
PharmAthene Announces Receipt of Payments from SIGA
PR Newswire - Fri Sep 16, 6:33AM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today announced it has received a series of payments from SIGA Technologies, Inc. totaling $90 million over the past month. Combined with $25 million in previous payments, PharmAthene has now received a total of $115 million plus $6.6 million of interest in partial payment of the SIGA judgement. Under the approved reorganization plan, SIGA has until November 30, 2016 to pay the remaining balance of $93.7 million plus interest.
PIP: 2.89 (-0.02)
PharmAthene Withdraws Protest Against HHS Over Anthrax Vaccine Bidding Process
PR Newswire - Thu Aug 25, 4:00PM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today announced that after discussions with the Biomedical Advanced Research and Development Authority (BARDA) the Company has withdrawn the protest filed on August 5, 2016.
PIP: 2.89 (-0.02)
PharmAthene Files Protest Against HHS Over Anthrax Vaccine Bidding Process
PR Newswire - Fri Aug 05, 11:56AM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today filed a formal protest against the Department of Health and Human Services, challenging its solicitation for a next-generation Anthrax vaccine provider.
PIP: 2.89 (-0.02)
PharmAthene Reports Second Quarter 2016 Financial and Operational Results
PR Newswire - Thu Aug 04, 3:17PM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today reported its financial and operational results for the second quarter of 2016.
PIP: 2.89 (-0.02)
PharmAthene Reports First Quarter 2016 Financial and Operational Results
PR Newswire - Mon May 09, 4:21PM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today reported its financial and operational results for the first quarter of 2016.
PIP: 2.89 (-0.02)
Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene
PR Newswire - Thu Dec 24, 7:00AM CST
PharmAthene, Inc. (NYSE MKT: PIP) announced today that the Delaware Supreme Court affirmed the Delaware Court of Chancery's decision to award PharmAthene lump sum expectation damages for the value of PharmAthene's lost profits for SIGA's smallpox antiviral, Tecovirimat. The Delaware Court of Chancery awarded PharmAthene $113 million in expectation damages plus interest and other costs, which if calculated based on the original decision (and including post-judgment interest) would provide for an estimated total of approximately $205 million. PharmAthene's ability to collect a monetary judgment, including post-petition interest, from SIGA remains subject to further proceedings in the Federal Bankruptcy Court. SIGA has filed a reorganization plan with the Court that provides for among other things, the process by which PharmAthene's judgment may be satisfied, but that plan has not been approved by the Bankruptcy Court and remains subject to change, withdrawal or rejection by the Court. A copy of the Delaware Supreme Court decision is available at: http://courts.delaware.gov/opinions/download.aspx?ID=234170.
PIP: 2.89 (-0.02)
SIGA Announces That Delaware Supreme Court Affirms Court of Chancery Opinion
BusinessWire - Wed Dec 23, 3:32PM CST
SIGA Technologies, Inc. a company specializing in the commercialization of solutions for serious unmet medical needs and biothreats, today announced that the Delaware Supreme Court affirmed the prior Court of Chancery Opinion in which the court awarded PharmAthene, Inc. approximately $195 million, including pre-judgment interest up to January 15, 2015.
PIP: 2.89 (-0.02)
PharmAthene Reports that SIGA has Filed its Reorganization Plan to Exit from Bankruptcy
PR Newswire - Tue Dec 15, 5:20PM CST
PharmAthene, Inc. (NYSE MKT: PIP) reported today that SIGA Technologies, Inc. filed with the U.S. Bankruptcy Court for the Southern District of New York a reorganization plan that sets out the terms and conditions under which SIGA will seek to exit from bankruptcy. The plan filed was negotiated between SIGA and the Statutory Creditor's Committee of which PharmAthene is a member. The plan is subject to approval by the bankruptcy court, on a timeline to be determined. A copy of the plan is available at: https://cases.primeclerk.com/siga/Home-Downlo...&id2=0.
PIP: 2.89 (-0.02)
PharmAthene Adopts Stockholder Rights Plan in an Effort to Protect Net Operating Loss Carryforwards
PR Newswire - Wed Nov 25, 3:11PM CST
PharmAthene, Inc. (NYSE MKT: PIP) announced today that its Board of Directors has adopted a stockholder rights plan (Rights Plan) in an effort to preserve the value of its net operating loss carryforwards (NOLs) under Section 382 of the Internal Revenue Code (Code).
PIP: 2.89 (-0.02)
PharmAthene Reports Third Quarter 2015 Financial and Operational Results
PR Newswire - Fri Nov 06, 3:00PM CST
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological threats, today reported its financial and operational results for the third quarter of 2015.
PIP: 2.89 (-0.02)
Anthrax - Pipeline Review, H2 2015
M2 - Fri Nov 06, 8:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/3bjw94/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Altimmune, Inc. - Aphios Corporation - Aradigm Corporation - Bavarian Nordic A/S - Bristol-Myers Squibb Company - Cellceutix Corporation - ContraFect Corporation - Dynavax Technologies Corporation - Elusys Therapeutics, Inc. - Emergent BioSolutions Inc. - Green Cross Corporation - Grifols, S.A. - Hawaii Biotech, Inc. - iBio, Inc. - Innovative Biologics, Inc. - Microbiotix, Inc. - NanoBio Corporation - Oragenics, Inc. - PaxVax - Pfenex Inc. - PharmAthene, Inc. - Protein Potential, LLC - ProThera Biologics, LLC. - PsiOxus Therapeutics Limited - Soligenix, Inc. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - United Therapeutics Corporation - VLP Biotech, Inc. For more information visit http://www.researchandmarkets.com/research/3bjw94/anthrax
DVAX: 11.41 (-0.21), TTPH: 3.83 (-0.04), ADRO: 14.54 (-0.25), EBS: 28.36 (-0.38), UTHR: 127.21 (+0.20), BMY: 56.48 (+0.06), PFNX: 9.10 (-0.25), PIP: 2.89 (-0.02), IBIO: 0.56 (unch), OGEN: 0.53 (-0.02)
PharmAthene Announces Conclusion of Oral Arguments In Its Litigation Against SIGA
PR Newswire - Wed Oct 07, 4:28PM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced that oral arguments in SIGA's appeal and PharmAthene's cross-appeal of the Delaware Court of Chancery's January 15, 2015 Final Order and Judgment in PharmAthene's litigation against SIGA took place in the Delaware Supreme Court today at 11:00 am ET. The oral argument proceedings may be viewed online at: http://livestream.com/DelawareSupremeCourt/ev.../101331469
PIP: 2.89 (-0.02)
Immunovaccine and PharmAthene Sign Exclusive Worldwide License Agreement to Develop and Commercialize an Anthrax Vaccine Formulated in DepoVax(TM)
Marketwired - Wed Jul 08, 6:05AM CDT
Immunovaccine Inc. (TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, announced today that it has entered into an exclusive worldwide license agreement with PharmAthene, Inc. (NYSE MKT: PIP) to develop and commercialize a Recombinant Protective Antigen Anthrax vaccine (rPA) candidate utilizing Immunovaccine's proprietary DepoVax(TM) vaccine platform.
IMV.TO: 0.78 (-0.02), PIP: 2.89 (-0.02)
US Military Accidentally Ships Live Anthrax via FedEx; These Are the Stocks to Watch in Its Wake
ACCESSWIRE - Mon Jun 01, 10:18AM CDT
WINDSOR, ON / ACCESSWIRE / June 1, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known, Biotech stocks making news and subsequent market moves.
FDX: 174.39 (+0.73), ROSG: 0.91 (unch), PIP: 2.89 (-0.02), NSPH: 1.69 (-0.01)
SIGA Technologies Receives NASDAQ Delisting Notification
BusinessWire - Wed Mar 18, 3:52PM CDT
SIGA Technologies, Inc. ("SIGA"
, a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced that it received a letter today from the Hearings Advisor for The NASDAQ Stock Market LLC ("NASDAQ" , indicating that the NASDAQ Hearings Panel has determined to delist the shares of the Company from the NASDAQ Stock Market and accordingly, suspend trading in the Company's shares effective at the open of business on March 20, 2015. SIGA expects its shares to continue to trade on the OTC Markets under the "SIGAQ" symbol.
PIP: 2.89 (-0.02)
PharmAthene Announces Receipt of Payments from SIGA
PR Newswire - Fri Sep 16, 6:33AM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today announced it has received a series of payments from SIGA Technologies, Inc. totaling $90 million over the past month. Combined with $25 million in previous payments, PharmAthene has now received a total of $115 million plus $6.6 million of interest in partial payment of the SIGA judgement. Under the approved reorganization plan, SIGA has until November 30, 2016 to pay the remaining balance of $93.7 million plus interest.
PIP: 2.89 (-0.02)
PharmAthene Withdraws Protest Against HHS Over Anthrax Vaccine Bidding Process
PR Newswire - Thu Aug 25, 4:00PM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today announced that after discussions with the Biomedical Advanced Research and Development Authority (BARDA) the Company has withdrawn the protest filed on August 5, 2016.
PIP: 2.89 (-0.02)
PharmAthene Files Protest Against HHS Over Anthrax Vaccine Bidding Process
PR Newswire - Fri Aug 05, 11:56AM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today filed a formal protest against the Department of Health and Human Services, challenging its solicitation for a next-generation Anthrax vaccine provider.
PIP: 2.89 (-0.02)
PharmAthene Reports Second Quarter 2016 Financial and Operational Results
PR Newswire - Thu Aug 04, 3:17PM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today reported its financial and operational results for the second quarter of 2016.
PIP: 2.89 (-0.02)
PharmAthene Reports First Quarter 2016 Financial and Operational Results
PR Newswire - Mon May 09, 4:21PM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today reported its financial and operational results for the first quarter of 2016.
PIP: 2.89 (-0.02)
Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene
PR Newswire - Thu Dec 24, 7:00AM CST
PharmAthene, Inc. (NYSE MKT: PIP) announced today that the Delaware Supreme Court affirmed the Delaware Court of Chancery's decision to award PharmAthene lump sum expectation damages for the value of PharmAthene's lost profits for SIGA's smallpox antiviral, Tecovirimat. The Delaware Court of Chancery awarded PharmAthene $113 million in expectation damages plus interest and other costs, which if calculated based on the original decision (and including post-judgment interest) would provide for an estimated total of approximately $205 million. PharmAthene's ability to collect a monetary judgment, including post-petition interest, from SIGA remains subject to further proceedings in the Federal Bankruptcy Court. SIGA has filed a reorganization plan with the Court that provides for among other things, the process by which PharmAthene's judgment may be satisfied, but that plan has not been approved by the Bankruptcy Court and remains subject to change, withdrawal or rejection by the Court. A copy of the Delaware Supreme Court decision is available at: http://courts.delaware.gov/opinions/download.aspx?ID=234170.
PIP: 2.89 (-0.02)
SIGA Announces That Delaware Supreme Court Affirms Court of Chancery Opinion
BusinessWire - Wed Dec 23, 3:32PM CST
SIGA Technologies, Inc. a company specializing in the commercialization of solutions for serious unmet medical needs and biothreats, today announced that the Delaware Supreme Court affirmed the prior Court of Chancery Opinion in which the court awarded PharmAthene, Inc. approximately $195 million, including pre-judgment interest up to January 15, 2015.
PIP: 2.89 (-0.02)
PharmAthene Reports that SIGA has Filed its Reorganization Plan to Exit from Bankruptcy
PR Newswire - Tue Dec 15, 5:20PM CST
PharmAthene, Inc. (NYSE MKT: PIP) reported today that SIGA Technologies, Inc. filed with the U.S. Bankruptcy Court for the Southern District of New York a reorganization plan that sets out the terms and conditions under which SIGA will seek to exit from bankruptcy. The plan filed was negotiated between SIGA and the Statutory Creditor's Committee of which PharmAthene is a member. The plan is subject to approval by the bankruptcy court, on a timeline to be determined. A copy of the plan is available at: https://cases.primeclerk.com/siga/Home-Downlo...&id2=0.
PIP: 2.89 (-0.02)
PharmAthene Adopts Stockholder Rights Plan in an Effort to Protect Net Operating Loss Carryforwards
PR Newswire - Wed Nov 25, 3:11PM CST
PharmAthene, Inc. (NYSE MKT: PIP) announced today that its Board of Directors has adopted a stockholder rights plan (Rights Plan) in an effort to preserve the value of its net operating loss carryforwards (NOLs) under Section 382 of the Internal Revenue Code (Code).
PIP: 2.89 (-0.02)
PharmAthene Reports Third Quarter 2015 Financial and Operational Results
PR Newswire - Fri Nov 06, 3:00PM CST
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological threats, today reported its financial and operational results for the third quarter of 2015.
PIP: 2.89 (-0.02)
Anthrax - Pipeline Review, H2 2015
M2 - Fri Nov 06, 8:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/3bjw94/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Altimmune, Inc. - Aphios Corporation - Aradigm Corporation - Bavarian Nordic A/S - Bristol-Myers Squibb Company - Cellceutix Corporation - ContraFect Corporation - Dynavax Technologies Corporation - Elusys Therapeutics, Inc. - Emergent BioSolutions Inc. - Green Cross Corporation - Grifols, S.A. - Hawaii Biotech, Inc. - iBio, Inc. - Innovative Biologics, Inc. - Microbiotix, Inc. - NanoBio Corporation - Oragenics, Inc. - PaxVax - Pfenex Inc. - PharmAthene, Inc. - Protein Potential, LLC - ProThera Biologics, LLC. - PsiOxus Therapeutics Limited - Soligenix, Inc. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - United Therapeutics Corporation - VLP Biotech, Inc. For more information visit http://www.researchandmarkets.com/research/3bjw94/anthrax
DVAX: 11.41 (-0.21), TTPH: 3.83 (-0.04), ADRO: 14.54 (-0.25), EBS: 28.36 (-0.38), UTHR: 127.21 (+0.20), BMY: 56.48 (+0.06), PFNX: 9.10 (-0.25), PIP: 2.89 (-0.02), IBIO: 0.56 (unch), OGEN: 0.53 (-0.02)
PharmAthene Announces Conclusion of Oral Arguments In Its Litigation Against SIGA
PR Newswire - Wed Oct 07, 4:28PM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced that oral arguments in SIGA's appeal and PharmAthene's cross-appeal of the Delaware Court of Chancery's January 15, 2015 Final Order and Judgment in PharmAthene's litigation against SIGA took place in the Delaware Supreme Court today at 11:00 am ET. The oral argument proceedings may be viewed online at: http://livestream.com/DelawareSupremeCourt/ev.../101331469
PIP: 2.89 (-0.02)
Immunovaccine and PharmAthene Sign Exclusive Worldwide License Agreement to Develop and Commercialize an Anthrax Vaccine Formulated in DepoVax(TM)
Marketwired - Wed Jul 08, 6:05AM CDT
Immunovaccine Inc. (TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, announced today that it has entered into an exclusive worldwide license agreement with PharmAthene, Inc. (NYSE MKT: PIP) to develop and commercialize a Recombinant Protective Antigen Anthrax vaccine (rPA) candidate utilizing Immunovaccine's proprietary DepoVax(TM) vaccine platform.
IMV.TO: 0.78 (-0.02), PIP: 2.89 (-0.02)
US Military Accidentally Ships Live Anthrax via FedEx; These Are the Stocks to Watch in Its Wake
ACCESSWIRE - Mon Jun 01, 10:18AM CDT
WINDSOR, ON / ACCESSWIRE / June 1, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known, Biotech stocks making news and subsequent market moves.
FDX: 174.39 (+0.73), ROSG: 0.91 (unch), PIP: 2.89 (-0.02), NSPH: 1.69 (-0.01)
SIGA Technologies Receives NASDAQ Delisting Notification
BusinessWire - Wed Mar 18, 3:52PM CDT
SIGA Technologies, Inc. ("SIGA"
, a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced that it received a letter today from the Hearings Advisor for The NASDAQ Stock Market LLC ("NASDAQ" , indicating that the NASDAQ Hearings Panel has determined to delist the shares of the Company from the NASDAQ Stock Market and accordingly, suspend trading in the Company's shares effective at the open of business on March 20, 2015. SIGA expects its shares to continue to trade on the OTC Markets under the "SIGAQ" symbol. PIP: 2.89 (-0.02)
(0)
(0)Scroll down for more posts ▼